Sponsor:
Repurposed Therapeutics, Inc.
Code:
NCT04272255
Conditions
Motion Sickness
Eligibility Criteria
Sex: All
Age: 18 - 59
Healthy Volunteers: Accepted
Interventions
scopolamine HBr
Transdermal Scopolamine
Brief summary:
Conditions
Motion Sickness
Study ID
NCT04272255
Start date
Apr 22, 2019
Status verified date
Feb, 2020
Completion date
Jul, 2020
Anticipated
Primary completion date
Jun, 2020
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 59
Healthy Volunteers: Accepted
Enrollment
300 participants
Anticipated
Allocation
Randomized
Intervention Model
Sequential
Primary purpose
Treatment
Arms
active comparator: DPI-386 nasal gel
placebo comparator: placebo nasal gel
experimental: Transderm Scop®
Interventions
scopolamine HBr
Transdermal Scopolamine
Primary outcome measure
Locations
NAMRU-D
Recruiting
Dayton, Ohio, United States, 45433
Contacts
Sponsor
Repurposed Therapeutics, Inc.
Last update posted
Feb 17, 2020
Last verified
Feb, 2020
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Repurposed Therapeutics, Inc. on 2020-02-17.